Coherus Oncology commercializes LOQTORZI, a next-generation PD-1 inhibitor approved for recurrent or metastatic nasopharyngeal carcinoma. The company advances a pipeline of immuno-oncology antibodies designed to overcome immune resistance and support combination therapies across multiple cancer types.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 7.6 | — | -56.6 | — |
| Q2 2025 | 10.3 | — | 297.8 | — |
| Q3 2025 | 11.6 | — | -35.5 | — |
| Q4 2025 | 12.8 | — | -37.6 | — |
| Q1 2026 | 12.3 | 62% | -38.3 | — |
| Q2 2026 | 14.3 | 39.5% | -20.6 | -106.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: First Capital, Inc. (FCAP), PepGen Inc. (PEPG), Eagle Nuclear Energy Corp. (NUCL), Acumen Pharmaceuticals, Inc. (ABOS), TOYO Co., Ltd. (TOYO), Texas Ventures Acquisition IV Corp. (TVIV)